ERAS
Erasca, Inc.
$19.18
+0.31
(+1.64%)
Mkt Cap
5.96B
Volume
4,119,855
52W Range
1.33-24.28
Sector
Healthcare
Beta
0.67
EPS (TTM)
-0.93
P/E Ratio
-8.45
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (124.55M) | (161.65M) | (125.04M) | (242.81M) | (122.76M) | (101.66M) | (12.04M) |
| EPS | -0.44 | -0.69 | -0.83 | -1.99 | -1.03 | -0.85 | -0.10 |
| Free Cash Flow | (95.58M) | (131.98M) | (102.99M) | (119.81M) | (98.48M) | (71.38M) | (10.97M) |
| FCF / Share | -0.34 | -0.56 | -0.69 | -0.98 | -0.83 | -0.60 | -0.09 |
| Operating CF | (95.45M) | (109.42M) | (101.22M) | (103.26M) | (79.60M) | (32.69M) | (10.38M) |
| Total Assets | 396.15M | 502.53M | 395.30M | 514.91M | 501.42M | 124.83M | 55.51M |
| Total Debt | 47.14M | 51.89M | 55.86M | 55.10M | 18.79M | 2.99M | 3.69M |
| Cash & Equiv | 73.81M | 67.74M | 93.08M | 284.22M | 360.49M | 65.38M | 29.58M |
| Book Value | 325.17M | 423.50M | 316.69M | 411.85M | 456.53M | 107.42M | (13.60M) |
| Return on Equity | -0.38 | -0.38 | -0.39 | -0.59 | -0.27 | -0.95 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (183.44M) | (29.09M) | (30.61M) | (33.88M) | (30.97M) | (32.23M) | (31.20M) | (63.20M) | (35.02M) | (29.70M) | (30.36M) | (31.78M) |
| EPS | -0.60 | -0.10 | -0.11 | -0.12 | -0.11 | -0.11 | -0.11 | -0.29 | -0.23 | -0.20 | -0.20 | -0.21 |
| Free Cash Flow | (27.42M) | (21.72M) | (21.66M) | (20.56M) | (31.64M) | (24.56M) | (22.42M) | (29.20M) | (33.29M) | (24.87M) | (24.36M) | (26.20M) |
| FCF / Share | -0.09 | -0.08 | -0.08 | -0.07 | -0.11 | -0.09 | -0.08 | -0.13 | -0.22 | -0.16 | -0.16 | -0.17 |
| Operating CF | (27.38M) | (21.71M) | (21.66M) | (20.53M) | (31.55M) | (24.56M) | (22.42M) | (29.18M) | (33.25M) | (24.79M) | (24.12M) | (25.95M) |
| Total Assets | 461.23M | 396.15M | 420.40M | 445.39M | 471.24M | 502.53M | 528.90M | 525.74M | 370.02M | 395.30M | 419.41M | 440.66M |
| Total Debt | 45.95M | 47.14M | 48.29M | 49.42M | 50.81M | 51.89M | 52.94M | 53.97M | 65.97M | 55.86M | 56.76M | 57.64M |
| Cash & Equiv | 47.26M | 73.81M | 70.23M | 66.14M | 70.48M | 67.74M | 68.89M | 172.80M | 76.73M | 93.08M | 112.86M | 138.79M |
| Book Value | 393.53M | 325.17M | 347.89M | 372.26M | 399.50M | 423.50M | 450.04M | 451.09M | 288.41M | 316.69M | 338.98M | 362.70M |
| Return on Equity | -0.47 | -0.09 | -0.09 | -0.09 | -0.08 | -0.08 | -0.07 | -0.14 | -0.12 | -0.09 | -0.09 | -0.09 |
ERAS News
Erasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERAS
ERAS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
ERAS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Erasca, Inc. Securities Lawsuit - Contact Levi & Korsinsky
ERAS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Erasca, Inc. Securities Lawsuit - Contact Levi & Korsinsky
ERASCA, INC. (ERAS) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Erasca, Inc. Investors of Upcoming Deadline
ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
ERAS DEADLINE NOTICE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
REMINDER: Erasca, Inc. Investors With Significant Losses Must Act By August 10, 2026 – Kirby McInerney LLP
ROSEN, A LONGSTANDING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS